CME 
JOBS 
OUTBREAKS 
PEER-TO-PEER 
QUIZZES & QUESTIONS 
MEDTECH The FDA has withdrawn its authorization for use of the monoclonal antibody sotrovimab in the treatment of COVID-19 in regions with a high frequency of the Omicron BA.2 subvariant. Data show that the authorized dose of the monoclonal antibody — 500 mg — is unlikely to be effective against the BA.2 COVID-19 subvariant.
Peer-influenced content. Sources you trust. No registration required. This is HCN.
